Verzenio™ (abemaciclib) – New drug approval
September 28, 2017 – The FDA announced the approval of Eli Lilly’s Verzenio (abemaciclib), for use in combination with Faslodex® (fulvestrant) for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy; and as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.
Top